Immunome (IMNM) Financials

$7.92 -0.64 (-7.48%)

Closing price 04:00 PM Eastern

Extended Trading

$7.92 +0.00 (+0.06%)

As of 07:49 PM Eastern

Annual Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-293	-107	-38
Consolidated Net Income / (Loss)	-293	-107	-37
Net Income / (Loss) Continuing Operations	-293	-107	-37
Total Pre-Tax Income	-293	-107	-37
Total Operating Income	-306	-110	-37
Total Gross Profit	9.04	14	0.00
Total Revenue	9.04	14	0.00
Operating Revenue	9.04	14	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	315	124	37
Selling, General & Admin Expense	33	20	14
Research & Development Expense	282	104	23
Total Other Income / (Expense), net	13	2.72	0.01
Interest Expense	-13	-2.72	-0.01
Basic Earnings per Share	($5.00)	($5.38)	($3.09)
Weighted Average Basic Shares Outstanding	58.64M	19.84M	12.13M
Diluted Earnings per Share	($5.00)	($5.38)	($3.09)
Weighted Average Diluted Shares Outstanding	58.64M	19.84M	12.13M
Weighted Average Basic & Diluted Shares Outstanding	86.95M	59.69M	12.22M

This table shows Immunome's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-80	-47	-36	-129	-93	-4.35	-5.56	-4.27	-28	-9.16
Consolidated Net Income / (Loss)	-80	-47	-36	-129	-93	-4.35	-5.56	-4.27	-7.79	-8.53
Net Income / (Loss) Continuing Operations	-80	-47	-36	-129	-93	-4.35	-5.56	-4.27	-7.79	-8.53
Total Pre-Tax Income	-80	-47	-36	-129	-93	-4.35	-5.56	-4.27	-7.79	-8.53
Total Operating Income	-83	-51	-40	-132	-95	-4.63	-5.77	-4.47	-7.79	-8.53
Total Gross Profit	2.74	2.91	2.36	1.03	3.83	3.57	4.26	2.36	-	0.00
Total Revenue	2.74	2.91	2.36	1.03	3.83	3.57	4.26	2.36	-	0.00
Operating Revenue	2.74	2.91	2.36	1.03	3.83	3.57	4.26	2.36	-	0.00
Total Operating Expenses	86	53	42	133	98	8.20	10	6.84	7.79	8.53
Selling, General & Admin Expense	10	9.53	6.98	6.01	8.04	4.38	4.32	2.92	3.54	3.31
Research & Development Expense	75	44	35	127	90	3.82	5.72	3.91	4.25	5.23
Total Other Income / (Expense), net	2.72	3.42	3.89	2.81	2.02	0.29	0.22	0.20	0.00	0.00
Interest Expense	-2.72	-3.42	-3.89	-2.81	-2.02	-0.29	-0.22	-0.20	-0.00	-0.00
Basic Earnings per Share	($1.11)	($0.78)	($0.60)	($2.51)	($4.21)	($0.36)	($0.46)	($0.35)	($0.64)	($0.75)
Weighted Average Basic Shares Outstanding	58.64M	60.21M	59.94M	51.54M	19.84M	12.20M	12.20M	12.18M	12.13M	12.13M
Diluted Earnings per Share	($1.11)	($0.78)	($0.60)	($2.51)	($4.21)	($0.36)	($0.46)	($0.35)	($0.64)	($0.75)
Weighted Average Diluted Shares Outstanding	58.64M	60.21M	59.94M	51.54M	19.84M	12.20M	12.20M	12.18M	12.13M	12.13M
Weighted Average Basic & Diluted Shares Outstanding	86.95M	62.42M	60.05M	59.97M	59.69M	42.73M	12.20M	12.22M	12.22M	12.13M

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	45	78	-29
Net Cash From Operating Activities	-111	-7.57	-29
Net Cash From Continuing Operating Activities	-111	-7.57	-29
Net Income / (Loss) Continuing Operations	-293	-107	-37
Consolidated Net Income / (Loss)	-293	-107	-37
Depreciation Expense	1.57	0.46	0.42
Amortization Expense	-2.36	-0.24	0.21
Non-Cash Adjustments To Reconcile Net Income	168	87	5.33
Changes in Operating Assets and Liabilities, net	15	12	2.24
Net Cash From Investing Activities	-85	-30	-0.25
Net Cash From Continuing Investing Activities	-85	-30	-0.25
Purchase of Property, Plant & Equipment	-7.17	-0.83	-0.25
Acquisitions	-46	0.00	-
Purchase of Investments	-187	-39	0.00
Divestitures	0.00	9.28	0.00
Sale and/or Maturity of Investments	155	0.00	-
Net Cash From Financing Activities	241	116	0.03
Net Cash From Continuing Financing Activities	241	116	0.03
Issuance of Debt	230	0.00	-
Issuance of Common Equity	20	125	0.00
Other Financing Activities, net	-9.47	-8.63	0.03

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-12	-9.76	-104	171	8.04	52	-6.01	24	-6.76	-7.57
Net Cash From Operating Activities	-42	-34	-23	-11	-17	-8.61	-5.67	24	-6.68	-7.57
Net Cash From Continuing Operating Activities	-42	-34	-23	-11	-17	-8.61	-5.67	24	-6.68	-7.57
Net Income / (Loss) Continuing Operations	-80	-47	-36	-129	-93	-4.35	-5.56	-4.27	-7.79	-8.53
Consolidated Net Income / (Loss)	-80	-47	-36	-129	-93	-4.35	-5.56	-4.27	-7.79	-8.53
Depreciation Expense	0.45	0.41	0.55	0.16	0.15	0.11	0.10	0.09	0.10	0.10
Amortization Expense	-0.39	-1.31	-0.23	-0.43	-0.74	0.39	0.06	0.05	0.17	0.01
Non-Cash Adjustments To Reconcile Net Income	33	12	9.50	114	84	1.09	1.03	1.16	1.36	1.34
Changes in Operating Assets and Liabilities, net	5.21	2.31	2.91	4.51	-8.14	-5.85	-1.30	27	-0.51	-0.49
Net Cash From Investing Activities	9.76	24	-82	-37	-30	-0.04	-0.34	-0.11	-0.07	-
Net Cash From Continuing Investing Activities	9.76	24	-82	-37	-30	-0.04	-0.34	-0.11	-0.07	-
Purchase of Property, Plant & Equipment	-1.13	-1.54	-2.34	-2.16	-0.35	-0.04	-0.34	-0.11	-0.07	-
Acquisitions	-0.25	-4.36	-6.66	-35	-	-	-	0.00	-	-
Purchase of Investments	-74	-	-	-	-39	-	-	-	-	-
Sale and/or Maturity of Investments	85	30	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	20	0.31	0.69	219	55	61	-	0.03	-	-
Net Cash From Continuing Financing Activities	20	0.31	0.69	219	55	61	-	0.03	-	-
Issuance of Common Equity	20	-	-	0.00	64	61	-	0.03	-	-
Other Financing Activities, net	0.09	0.31	0.69	-11	-8.50	-0.13	-	0.00	-	-

This table presents Immunome's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	240	149	24
Total Current Assets	221	145	23
Cash & Equivalents	143	99	20
Short-Term Investments	74	39	0.00
Prepaid Expenses	4.04	6.56	2.33
Plant, Property, & Equipment, net	10	2.07	0.68
Total Noncurrent Assets	8.79	1.76	0.72
Other Noncurrent Operating Assets	8.79	1.76	0.72
Total Liabilities & Shareholders' Equity	240	149	24
Total Liabilities	59	29	7.39
Total Current Liabilities	54	22	7.33
Accounts Payable	14	3.31	2.40
Accrued Expenses	33	8.03	4.93
Current Deferred Revenue	6.94	10	0.00
Total Noncurrent Liabilities	4.77	6.83	0.06
Noncurrent Deferred Revenue	0.00	5.49	0.00
Other Noncurrent Operating Liabilities	4.77	1.34	0.06
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	181	120	17
Total Preferred & Common Equity	181	120	17
Preferred Stock	0.00	0.00	0.00
Total Common Equity	181	120	17
Common Stock	697	343	133
Retained Earnings	-516	-223	-116
Accumulated Other Comprehensive Income / (Loss)	0.06	0.02	0.00

This table presents Immunome's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	257	296	320	93	41	48	31
Total Current Assets	244	284	313	91	40	47	29
Cash & Equivalents	156	165	270	91	38	44	27
Short-Term Investments	85	113	40	-	-	-	-
Prepaid Expenses	3.91	5.93	3.62	0.77	1.11	2.11	2.16
Plant, Property, & Equipment, net	7.17	6.10	4.30	1.17	1.20	0.92	0.70
Total Noncurrent Assets	5.69	5.84	2.13	0.58	0.71	0.66	0.60
Other Noncurrent Operating Assets	5.69	5.84	2.13	0.58	0.71	0.66	0.60
Total Liabilities & Shareholders' Equity	257	296	320	93	41	48	31
Total Liabilities	42	42	34	87	32	34	7.46
Total Current Liabilities	40	40	31	23	26	25	7.37
Accounts Payable	3.52	7.05	7.18	2.79	3.70	3.31	3.14
Accrued Expenses	26	20	11	3.37	5.03	3.31	4.23
Current Deferred Revenue	9.68	13	13	17	18	18	-
Total Noncurrent Liabilities	2.46	2.48	3.41	64	5.71	9.42	0.09
Noncurrent Deferred Revenue	0.00	0.00	2.21	2.85	5.71	9.42	-
Other Noncurrent Operating Liabilities	2.46	2.48	1.21	61	0.00	0.00	0.09
Total Equity & Noncontrolling Interests	215	254	286	6.08	9.34	14	23
Total Preferred & Common Equity	215	254	286	6.08	9.34	14	23
Preferred Stock	0.00	0.00	0.00	0.00	-	0.00	0.00
Total Common Equity	215	254	286	6.08	9.34	14	23
Common Stock	650	642	638	136	135	134	131
Retained Earnings	-436	-388	-352	-130	-126	-120	-108
Accumulated Other Comprehensive Income / (Loss)	0.07	0.00	0.00	-	-	-	-

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-35.50%	0.00%	0.00%
EBITDA Growth	-180.47%	-201.39%	-51.47%
EBIT Growth	-179.19%	-196.82%	-49.39%
NOPAT Growth	-179.19%	-196.82%	-46.41%
Net Income Growth	-174.29%	-189.48%	-49.31%
EPS Growth	7.06%	-74.11%	-44.39%
Operating Cash Flow Growth	-1,363.98%	73.62%	-57.41%
Free Cash Flow Firm Growth	-216.01%	-167.54%	-59.81%
Invested Capital Growth	-97.91%	-397.55%	-251.53%
Revenue Q/Q Growth	-10.74%	37.54%	0.00%
EBITDA Q/Q Growth	3.87%	-406.06%	0.55%
EBIT Q/Q Growth	3.68%	-383.28%	0.15%
NOPAT Q/Q Growth	3.68%	-383.28%	0.15%
Net Income Q/Q Growth	4.06%	-386.41%	0.18%
EPS Q/Q Growth	38.27%	-197.24%	0.64%
Operating Cash Flow Q/Q Growth	-28.54%	-335.91%	0.42%
Free Cash Flow Firm Q/Q Growth	30.33%	-195.94%	0.52%
Invested Capital Q/Q Growth	-43.27%	78.41%	8.11%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	0.00%
EBITDA Margin	-3,391.18%	-779.81%	0.00%
Operating Margin	-3,382.37%	-781.35%	0.00%
EBIT Margin	-3,382.37%	-781.35%	0.00%
Profit (Net Income) Margin	-3,240.38%	-761.92%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	95.80%	97.51%	99.99%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-194.63%	-156.45%	-113.81%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-157.31%	-126.93%	0.00%
Return on Assets (ROA)	-150.71%	-123.77%	0.00%
Return on Common Equity (ROCE)	-194.63%	-156.45%	-113.81%
Return on Equity Simple (ROE_SIMPLE)	-161.71%	-89.09%	-221.56%
Net Operating Profit after Tax (NOPAT)	-214	-77	-26
NOPAT Margin	-2,367.66%	-546.95%	0.00%
Net Nonoperating Expense Percent (NNEP)	-44.40%	-38.03%	-31.82%
Return On Investment Capital (ROIC_SIMPLE)	-118.16%	-63.96%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	364.51%	140.23%	0.00%
R&D to Revenue	3,117.86%	741.13%	0.00%
Operating Expenses to Revenue	3,482.37%	881.35%	0.00%
Earnings before Interest and Taxes (EBIT)	-306	-110	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-307	-109	-36
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.66	3.81	1.61
Price to Tangible Book Value (P/TBV)	3.66	3.81	1.61
Price to Revenue (P/Rev)	73.32	32.62	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	49.28	22.76	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.18	-1.16	-1.07
Leverage Ratio	1.29	1.26	1.26
Compound Leverage Factor	1.24	1.23	1.26
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	0.40	6.13	-8.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	4.08	6.63	3.09
Quick Ratio	4.00	6.33	2.77
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-196	-62	-23
Operating Cash Flow to CapEx	-1,544.60%	-910.71%	-11,568.55%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.05	0.16	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.48	10.18	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-36	-18	-3.67
Invested Capital Turnover	-0.33	-1.28	0.00
Increase / (Decrease) in Invested Capital	-18	-15	-2.63
Enterprise Value (EV)	446	319	6.48
Market Capitalization	663	457	27
Book Value per Share	$2.90	$2.81	$1.37
Tangible Book Value per Share	$2.90	$2.81	$1.37
Total Capital	181	120	17
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-217	-138	-20
Capital Expenditures (CapEx)	7.17	0.83	0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-50	-15	-5.01
Debt-free Net Working Capital (DFNWC)	167	123	15
Net Working Capital (NWC)	167	123	15
Net Nonoperating Expense (NNE)	79	30	11
Net Nonoperating Obligations (NNO)	-217	-138	-20
Total Depreciation and Amortization (D&A)	-0.80	0.22	0.63
Debt-free, Cash-free Net Working Capital to Revenue	-556.03%	-108.92%	0.00%
Debt-free Net Working Capital to Revenue	1,847.49%	876.54%	0.00%
Net Working Capital to Revenue	1,847.49%	876.54%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($5.00)	($5.38)	($3.09)
Adjusted Weighted Average Basic Shares Outstanding	58.64M	19.84M	12.13M
Adjusted Diluted Earnings per Share	($5.00)	($5.38)	($3.09)
Adjusted Weighted Average Diluted Shares Outstanding	58.64M	19.84M	12.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	86.95M	59.69M	12.22M
Normalized Net Operating Profit after Tax (NOPAT)	-214	-77	-26
Normalized NOPAT Margin	-2,367.66%	-546.95%	0.00%
Pre Tax Income Margin	-3,240.38%	-761.92%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-28.44%	-18.37%	-44.55%	-56.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	12.95%	-1,143.63%	-606.70%	-2,966.71%	-1,165.31%	50.89%	36.22%	62.47%	2.58%	-13.31%
EBIT Growth	12.34%	-990.48%	-593.04%	-2,859.05%	-1,115.53%	45.71%	35.32%	61.64%	0.73%	-10.59%
NOPAT Growth	12.34%	-990.48%	-593.04%	-2,859.05%	-1,115.53%	45.71%	35.32%	61.64%	0.73%	-10.50%
Net Income Growth	13.37%	-984.00%	-550.03%	-2,932.60%	-1,089.75%	49.08%	37.73%	63.36%	0.84%	-10.53%
EPS Growth	73.63%	-116.67%	-30.43%	-617.14%	-557.81%	52.00%	37.84%	63.54%	3.03%	-15.38%
Operating Cash Flow Growth	-140.91%	-296.65%	-312.79%	-146.21%	-161.24%	-13.78%	29.68%	479.12%	1.79%	-82.65%
Free Cash Flow Firm Growth	22.19%	-222.47%	-257.61%	-541.59%	-1,728.99%	2,354.59%	1,999.00%	2,244.51%	-19.30%	68.58%
Invested Capital Growth	-97.91%	70.17%	15.69%	21.03%	-397.55%	-2,017.30%	-565.10%	-510.63%	-251.53%	-175.45%
Revenue Q/Q Growth	-5.91%	23.10%	129.74%	-73.11%	7.32%	-16.37%	80.33%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-61.23%	-29.57%	70.06%	-39.69%	-2,203.26%	26.37%	-29.91%	42.57%	10.61%	4.37%
EBIT Q/Q Growth	-64.23%	-26.28%	69.76%	-39.77%	-1,943.02%	19.75%	-29.12%	42.58%	8.75%	4.39%
NOPAT Q/Q Growth	-64.23%	-26.28%	69.76%	-39.77%	-1,943.02%	19.75%	-29.12%	42.58%	8.75%	4.39%
Net Income Q/Q Growth	-70.38%	-30.39%	72.10%	-39.79%	-2,031.97%	21.81%	-30.14%	45.16%	8.75%	4.38%
EPS Q/Q Growth	-42.31%	-30.00%	76.10%	40.38%	-1,069.44%	21.74%	-31.43%	45.31%	14.67%	-1.35%
Operating Cash Flow Q/Q Growth	-23.10%	-46.03%	-109.46%	36.02%	-102.68%	-51.98%	-123.45%	461.71%	11.73%	6.07%
Free Cash Flow Firm Q/Q Growth	57.55%	-190.78%	67.11%	-91.68%	-166.82%	274.20%	-7.86%	893.91%	17.64%	-215.18%
Invested Capital Q/Q Growth	-43.27%	-2.89%	-1.58%	-32.17%	78.41%	-190.82%	4.86%	-732.75%	8.11%	8.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	-3,028.16%	-1,767.15%	-1,678.85%	-12,883.77%	-2,489.28%	-115.99%	-131.74%	-182.87%	0.00%	0.00%
Operating Margin	-3,030.31%	-1,736.15%	-1,692.43%	-12,857.05%	-2,473.94%	-129.96%	-135.42%	-189.13%	0.00%	0.00%
EBIT Margin	-3,030.31%	-1,736.15%	-1,692.43%	-12,857.05%	-2,473.94%	-129.96%	-135.42%	-189.13%	0.00%	0.00%
Profit (Net Income) Margin	-2,930.94%	-1,618.56%	-1,528.00%	-12,584.26%	-2,421.17%	-121.88%	-130.35%	-180.63%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.72%	93.23%	90.28%	97.88%	97.87%	93.78%	96.26%	95.50%	99.99%	99.99%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-194.63%	-276.36%	-199.56%	-154.98%	-156.45%	-150.60%	-132.00%	-114.09%	-113.81%	-94.92%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-140.94%	-100.47%	-108.11%	-886.55%	-401.88%	-21.41%	-22.31%	-9.33%	0.00%	0.00%
Return on Assets (ROA)	-136.32%	-93.67%	-97.60%	-867.74%	-393.31%	-20.08%	-21.47%	-8.91%	0.00%	0.00%
Return on Common Equity (ROCE)	-194.63%	-276.36%	-199.56%	-154.98%	-156.45%	-150.60%	-132.00%	-114.09%	-113.81%	-94.92%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-142.08%	-103.45%	-81.25%	0.00%	-361.39%	-280.00%	-212.91%	0.00%	-160.12%
Net Operating Profit after Tax (NOPAT)	-58	-35	-28	-93	-66	-3.24	-4.04	-3.13	-5.45	-5.97
NOPAT Margin	-2,121.22%	-1,215.31%	-1,184.70%	-8,999.93%	-1,731.76%	-90.97%	-94.79%	-132.39%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-12.47%	-7.10%	-5.12%	-20.83%	-33.29%	-1.87%	-4.15%	-2.61%	-6.71%	-6.14%
Return On Investment Capital (ROIC_SIMPLE)	-32.06%	-	-	-	-55.27%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	381.52%	327.35%	295.18%	583.58%	210.14%	122.72%	101.34%	123.60%	0.00%	0.00%
R&D to Revenue	2,748.79%	1,508.80%	1,497.25%	12,373.47%	2,363.80%	107.24%	134.08%	165.52%	0.00%	0.00%
Operating Expenses to Revenue	3,130.31%	1,836.15%	1,792.43%	12,957.05%	2,573.94%	229.96%	235.42%	289.13%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-83	-51	-40	-132	-95	-4.63	-5.77	-4.47	-7.79	-8.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-83	-51	-40	-133	-95	-4.14	-5.62	-4.32	-7.53	-8.42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.66	4.09	2.86	5.16	3.81	16.77	10.35	4.40	1.61	2.33
Price to Tangible Book Value (P/TBV)	3.66	4.09	2.86	5.16	3.81	16.77	10.35	4.40	1.61	2.33
Price to Revenue (P/Rev)	73.32	86.68	67.29	116.16	32.62	10.00	14.58	25.78	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	49.28	62.97	41.48	91.74	22.76	1.10	8.78	6.99	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	3.51	13.69	8.89	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.17	9.53	3.48	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.18	-1.50	-1.20	-1.18	-1.16	-4.04	-1.84	-1.69	-1.07	-1.07
Leverage Ratio	1.29	1.58	1.28	1.23	1.26	4.24	2.03	1.85	1.26	1.20
Compound Leverage Factor	1.25	1.48	1.16	1.20	1.24	3.98	1.95	1.77	1.26	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	3.46	10.52	9.02	24.05	6.46	-0.43	-2.36	-2.15	-4.88	-0.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.08	6.17	7.12	10.18	6.63	3.96	1.50	1.87	3.09	3.97
Quick Ratio	4.00	6.07	6.98	10.07	6.33	3.92	1.46	1.79	2.77	3.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-40	-95	-33	-99	-52	77	21	22	-2.82	-3.43
Operating Cash Flow to CapEx	-3,735.35%	-2,220.08%	-998.17%	-516.17%	-5,002.58%	-23,927.78%	-1,667.06%	22,804.72%	-9,281.94%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.05	0.06	0.06	0.07	0.16	0.16	0.16	0.05	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.48	2.43	2.95	4.86	10.18	10.87	6.59	2.83	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-36	-25	-25	-24	-18	-85	-29	-31	-3.67	-3.99
Invested Capital Turnover	-0.33	-0.18	-0.40	-0.46	-1.28	-0.23	-0.40	-0.13	0.00	0.00
Increase / (Decrease) in Invested Capital	-18	59	4.56	6.43	-15	-81	-25	-26	-2.63	-2.54
Enterprise Value (EV)	446	638	447	1,164	319	11	58	17	6.48	27
Market Capitalization	663	878	726	1,473	457	102	97	61	27	54
Book Value per Share	$2.90	$3.58	$4.23	$4.78	$2.81	$0.50	$0.76	$1.13	$1.37	$1.90
Tangible Book Value per Share	$2.90	$3.58	$4.23	$4.78	$2.81	$0.50	$0.76	$1.13	$1.37	$1.90
Total Capital	181	215	254	286	120	6.08	9.34	14	17	23
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-217	-240	-278	-310	-138	-91	-38	-44	-20	-27
Capital Expenditures (CapEx)	1.13	1.54	2.34	2.16	0.35	0.04	0.34	0.11	0.07	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-50	-36	-34	-27	-15	-22	-25	-23	-5.01	-5.21
Debt-free Net Working Capital (DFNWC)	167	205	244	283	123	68	13	22	15	22
Net Working Capital (NWC)	167	205	244	283	123	68	13	22	15	22
Net Nonoperating Expense (NNE)	22	12	8.12	37	26	1.10	1.52	1.14	2.34	2.56
Net Nonoperating Obligations (NNO)	-217	-240	-278	-310	-138	-91	-38	-44	-20	-27
Total Depreciation and Amortization (D&A)	0.06	-0.90	0.32	-0.28	-0.59	0.50	0.16	0.15	0.26	0.11
Debt-free, Cash-free Net Working Capital to Revenue	-556.03%	-351.64%	-314.99%	-214.05%	-108.92%	-219.17%	-381.50%	-961.04%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	1,847.49%	2,019.07%	2,266.17%	2,227.85%	876.54%	670.16%	198.19%	918.15%	0.00%	0.00%
Net Working Capital to Revenue	1,847.49%	2,019.07%	2,266.17%	2,227.85%	876.54%	670.16%	198.19%	918.15%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.11)	($0.78)	($0.60)	($2.51)	($4.21)	($0.36)	($0.46)	($0.35)	($0.64)	($0.75)
Adjusted Weighted Average Basic Shares Outstanding	58.64M	60.21M	59.94M	51.54M	19.84M	12.20M	12.20M	12.18M	12.13M	12.13M
Adjusted Diluted Earnings per Share	($1.11)	($0.78)	($0.60)	($2.51)	($4.21)	($0.36)	($0.46)	($0.35)	($0.64)	($0.75)
Adjusted Weighted Average Diluted Shares Outstanding	58.64M	60.21M	59.94M	51.54M	19.84M	12.20M	12.20M	12.18M	12.13M	12.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	86.95M	62.42M	60.05M	59.97M	59.69M	42.73M	12.20M	12.22M	12.22M	12.13M
Normalized Net Operating Profit after Tax (NOPAT)	-58	-35	-28	-93	-66	-3.24	-4.04	-3.13	-5.45	-5.97
Normalized NOPAT Margin	-2,121.22%	-1,215.31%	-1,184.70%	-8,999.93%	-1,731.76%	-90.97%	-94.79%	-132.39%	0.00%	0.00%
Pre Tax Income Margin	-2,930.94%	-1,618.56%	-1,528.00%	-12,584.26%	-2,421.17%	-121.88%	-130.35%	-180.63%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Immunome's Financials

When does Immunome's financial year end?

According to the most recent income statement we have on file, Immunome's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Immunome's net income changed over the last 2 years?

Immunome's net income appears to be on an upward trend, with a most recent value of -$292.96 million in 2024, rising from -$36.90 million in 2022. The previous period was -$106.81 million in 2023. Check out Immunome's forecast to explore projected trends and price targets.

What is Immunome's operating income?

Immunome's total operating income in 2024 was -$305.80 million, based on the following breakdown:

Total Gross Profit: $9.04 million
Total Operating Expenses: $314.84 million

How has Immunome revenue changed over the last 2 years?

Over the last 2 years, Immunome's total revenue changed from $0.00 in 2022 to $9.04 million in 2024, a change of 904,100,000.0%.

How much debt does Immunome have?

Immunome's total liabilities were at $59.08 million at the end of 2024, a 106.1% increase from 2023, and a 699.1% increase since 2022.

How much cash does Immunome have?

In the past 2 years, Immunome's cash and equivalents has ranged from $20.32 million in 2022 to $143.35 million in 2024, and is currently $143.35 million as of their latest financial filing in 2024.

How has Immunome's book value per share changed over the last 2 years?

Over the last 2 years, Immunome's book value per share changed from 1.37 in 2022 to 2.90 in 2024, a change of 111.4%.

Related Companies

This page (NASDAQ:IMNM) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Financials

Frequently Asked Questions About Immunome's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Financials

Annual Income Statements for Immunome

Quarterly Income Statements for Immunome

Annual Cash Flow Statements for Immunome

Quarterly Cash Flow Statements for Immunome

Annual Balance Sheets for Immunome

Quarterly Balance Sheets for Immunome

Annual Metrics And Ratios for Immunome

Quarterly Metrics And Ratios for Immunome

Frequently Asked Questions About Immunome's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools